Fig. 5: In vivo lipid-mediated delivery of Cas9:sgRNA complexes improves OHC function, hearing and auditory behavioral function. | Nature Communications

Fig. 5: In vivo lipid-mediated delivery of Cas9:sgRNA complexes improves OHC function, hearing and auditory behavioral function.

From: Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Fig. 5

a DPOAE thresholds in Atp2b2Obl/+ ears injected with Cas9:Atp2b2-mut1 sgRNA:Lipo2000 (blue), uninjected Atp2b2Obl/+ ears (red), and wild-type C3H ears (green) after 4 weeks of age. b ABR thresholds in Atp2b2Obl/+ ears injected with Cas9:Atp2b2-mut1 sgRNA:Lipo2000 (blue), uninjected Atp2b2Obl/+ ears (red) (the thresholds for each individual mouse could be found in Source data file), and wild-type C3H ears (green) after 4 weeks of age. c Representative ABR waveforms illustrating a threshold of 40 dB (red trace, left) at 16 kHz in a Cas9:Atp2b2-mut1 gRNA injected Atp2b2Obl/+ inner ear compared to the threshold of 85 dB (red trace, right) of the uninjected contralateral ear of the same mouse 4 weeks after injection. d Amplitudes of ABR Wave 1 at 16 kHz in Cas9:Atp2b2-mut1 sgRNA:Lipo2000-injected ears (blue), uninjected ears (red), and wild-type C3H ears (green) after 4 weeks of age. e Startle responses in Cas9:Atp2b2-mut1 sgRNA:Lipo2000 injected mice (blue), uninjected mice (red) and wild-type C3H ears (green) at 8 weeks post injection. Statistical tests were two-way ANOVA with Bonferroni correction for multiple comparisons: **p < 0.01, ***p < 0.001, and ****p < 0.0001. Values and error bars are mean ± SEM.

Back to article page